News about "Zydus Lifesciences"

Zydus Lifesciences and Sunshine Healthcare Form JV to Boost Pharma Manufacturing in Sri Lanka

Zydus Lifesciences and Sunshine Healthcare launch a Joint Venture (JV) to develop a pharma manufacturing facility at BOI Horana, strengthening Sri Lanka’s supply of quality medicines.

Zydus Lifesciences | 29/06/2026 | By News Bureau

Assertio Announces Completion of Merger with Zydus Lifesciences

Assertio has completed its merger with Zydus Lifesciences, becoming a wholly owned subsidiary of the company. Following the acquisition, Assertio shares have been delisted from Nasdaq, with shareholders receiving USD 23.50 per share in cash.

Zydus Lifesciences | 19/06/2026 | By News Bureau

US FDA Grants Priority Review to Zydus Therapeutics' Saroglitazar for Primary Biliary Cholangitis

Zydus Therapeutics has received US FDA Priority Review (PR) for its New Drug Application (NDA) for saroglitazar in the treatment of Primary Biliary Cholangitis (PBC), supported by phase 3 EPICS-III trial results demonstrating significant biochemical response, with detailed data to be presented at the EASL Congress 2026.

Zydus Lifesciences | 29/05/2026 | By News Bureau

Zydus Lifesciences Completes Investment in Torrent Urja 25 with Rs 90.18 Million Share Subscription

Zydus Lifesciences and its subsidiaries have completed the final tranche of investment in Torrent Urja 25, subscribing to equity shares worth Rs 90.18 million and concluding the transaction initiated under the Share Subscription and Shareholders’ Agreements (SSSAs).

Zydus Lifesciences | 20/05/2026 | By News Bureau |  135

Zydus Lifesciences Launches Aerolife Mini, India's First Portable Foldable Spacer

Zydus introduces Aerolife Mini, a compact pMDI enhancer designed to improve inhaler drug delivery and patient compliance in respiratory care through a convenient, foldable design.

Zydus Lifesciences | 20/03/2026 | By News Bureau |  142

Zydus and Torrent Pharma Sign Licensing Deal to Co-Market Semaglutide in India

Zydus Lifesciences and Torrent Pharmaceuticals have entered a licensing agreement to co-market Semaglutide injection in India, aiming to improve access for patients with poorly controlled Type 2 Diabetes Mellitus and support chronic weight management through advanced, innovative therapy.

Zydus Lifesciences | 19/03/2026 | By News Bureau |  190

Lupin and Zydus Partner to Co-Market Semaglutide Injection in India

Lupin has secured semi-exclusive rights to co-market Zydus’ Semaglutide injection in India under the brands Semanext and Livarise, while Zydus will continue marketing it under the brand names SEMAGLYNTM, MASHEMATM and ALTERMETM.

Zydus Lifesciences | 18/03/2026 | By News Bureau |  257

US FDA Approves Zydus' Cevimeline Hydrochloride Capsules 30 mg

Zydus Lifesciences has received USFDA approval for Cevimeline Hydrochloride Capsules 30 mg for treating dry mouth associated with Sjögren’s syndrome. The capsules will be manufactured at the company’s SEZ-II facility in Ahmedabad.

Zydus Lifesciences | 13/03/2026 | By News Bureau |  192

Zydus Gets USFDA Tentative Nod for Dapagliflozin Tablets

Zydus has received tentative approval from the US Food and Drug Administration (USFDA) for dapagliflozin tablets in 5 mg and 10 mg strengths, paving the way for the company’s entry into the US market subject to final approval.

Zydus Lifesciences | 06/02/2026 | By News Bureau |  161

Zydus Launches World's First Nivolumab Biosimilar 'Tishtha' in India

Zydus Lifesciences has launched Tishtha, the world’s first biosimilar of the immunotherapy drug nivolumab, in India, aimed at expanding access to advanced cancer care by offering the treatment at nearly one-fourth the cost of the reference product for patients with multiple cancer types.

Zydus Lifesciences | 23/01/2026 | By News Bureau |  691